solian 100 tablets
sanofi - amisulpride - oral tablet - 100mg
solian 100mg/ml oral solution
sanofi - amisulpride - oral solution - 100mg/1ml
solian 50 tablets
dowelhurst ltd - amisulpride - oral tablet - 50mg
solian 100 tablets
waymade healthcare plc - amisulpride - oral tablet - 100mg
solian 100 tablets
sigma pharmaceuticals plc - amisulpride - oral tablet - 100mg
solian 400 mg film-coated tablets
originalis b.v. - amisulpride - film-coated tablet - 400 milligram(s) - amisulpride
solian 100mg scored tablet
sanofi-aventis (malaysia) sdn. bhd. - amisulpride -
solian 400mg scored film-coated tablet
sanofi-aventis (malaysia) sdn. bhd. - amisulpride -
solitaire x revascularization device - thrombectomy wire-net
medtronic australasia pty ltd - 61779 - thrombectomy wire-net - the solitaire? x revascularization device is designed to restore blood flow by removing thrombus in patients experiencing ischemic stroke due to large intracranial vessel occlusion. the device is designed for use in the neurovasculature such as the internal carotid artery, m1 and m2 segments of the middle cerebral artery, basilar, and the vertebral arteries. the solitaire? x revascularization device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent,proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (iv t-pa). endovascular therapy with the device should be started within 6 hours of symptom onset. 2. the solitaire? x revascularization device is indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. patients who are ineligible for iv t-pa or who fail iv t-pa therapy are candidates for treatment. 3. the solitaire? x revascularization device is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent,proximal anterior circulation, large vessel occlusion of the internal carotid artery (ica) or middle cerebral artery (mca)-m1 segments with smaller core infarcts (<70 cc by cta or mra, <25 cc by mr-dwi). endovascular therapy with the device should start within 6-16 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (iv t-pa) or who fail iv t-pa therapy.
solian 50 mg tablet
sanofi-aventis south africa (pty) ltd - tablet - see ingredients - each tablet contains amisulpride 50,0 mg